See the Latest from VoA
Voices of Alzheimer's Applauds Medicare's Progress in Removing CED for Amyloid PET Scans but Calls Out its Failure to Ensure Expeditious and Equitable Coverage.
Statements and letters from VoA
Helpful Resources and Information
Want to learn more about lecanemab? View our fact sheet here answering real questions from those living with Alzheimer’s disease and members of the public on the latest treatment to enter the market.
Our Voice
Our mission and our leadership are driven by the specific priorities of the more than 6 million people living in the US with Alzheimer’s as well as their families, friends, loved ones and those who may develop it in the future. It’s time that people living with Alzheimer’s, as well as everyone affected by the condition, has a voice.